Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy
Lawrence Kleinberg Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA Abstract: Polifeprosan 20 with carmustine (GLIADEL®) polymer implant wafer is a biodegradable compound containing 3.85% carmustine (BCNU, bischloroethylnitroso...
Main Author: | Kleinberg L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-11-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/1polifeprosan-20-385-carmustine-slow-release-wafer-in-malignant-g-peer-reviewed-article-PPA |
Similar Items
-
Three-Dimensional Simulation of Carmustine Delivery to a Patient-Specific Brain Tumor
by: Arifin, Davis Yohanes, et al.
Published: (2007) -
Identification of a Prognostic Microenvironment-Related Gene Signature in Glioblastoma Patients Treated with Carmustine Wafers
by: Ivana Manini, et al.
Published: (2022-07-01) -
Prognostic effects of O6-Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants
by: Mao-Yu Chen, et al.
Published: (2017-01-01) -
Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
by: Luca Ricciardi, et al.
Published: (2022-06-01) -
Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
by: Claire Gazaille, et al.
Published: (2021-11-01)